Femasys (FEMY)
(Delayed Data from NSDQ)
$1.27 USD
-0.06 (-4.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:10 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.27 USD
-0.06 (-4.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:10 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Zacks News
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 32.29% and 3.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?